Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Array-based cytogenetic tests

This article was originally published in The Gray Sheet

Executive Summary

FDA will host a workshop on array-based cytogenetic tests June 30 to address challenges in performance evaluation, determining clinical significance, and results reporting and interpretation. Cytogenetic tests detect pathological genomic copy number changes in a patient's DNA to identify abnormalities. FDA says these complex, array-based tests challenge "the traditional method of FDA review." The meeting will take place in Bethesda, Md. Comments on questions posed in a June 8 Federal Register 1notice are due July 30
Advertisement

Related Content

FDA Attempts To Carve Out Regulatory Policy For Cytogenetic Tests

Topics

Advertisement
UsernamePublicRestriction

Register

MT028983

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel